首页> 美国卫生研究院文献>Springer Open Choice >Pluripotent Stem Cells for Retinal Tissue Engineering: Current Status and Future Prospects
【2h】

Pluripotent Stem Cells for Retinal Tissue Engineering: Current Status and Future Prospects

机译:视网膜组织工程多能干细胞的现状和未来展望

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The retina is a very fine and layered neural tissue, which vitally depends on the preservation of cells, structure, connectivity and vasculature to maintain vision. There is an urgent need to find technical and biological solutions to major challenges associated with functional replacement of retinal cells. The major unmet challenges include generating sufficient numbers of specific cell types, achieving functional integration of transplanted cells, especially photoreceptors, and surgical delivery of retinal cells or tissue without triggering immune responses, inflammation and/or remodeling. The advances of regenerative medicine enabled generation of three-dimensional tissues (organoids), partially recreating the anatomical structure, biological complexity and physiology of several tissues, which are important targets for stem cell replacement therapies. Derivation of retinal tissue in a dish creates new opportunities for cell replacement therapies of blindness and addresses the need to preserve retinal architecture to restore vision. Retinal cell therapies aimed at preserving and improving vision have achieved many improvements in the past ten years. Retinal organoid technologies provide a number of solutions to technical and biological challenges associated with functional replacement of retinal cells to achieve long-term vision restoration. Our review summarizes the progress in cell therapies of retina, with focus on human pluripotent stem cell-derived retinal tissue, and critically evaluates the potential of retinal organoid approaches to solve a major unmet clinical need—retinal repair and vision restoration in conditions caused by retinal degeneration and traumatic ocular injuries. We also analyze obstacles in commercialization of retinal organoid technology for clinical application.
机译:视网膜是非常细微且分层的神经组织,它在很大程度上取决于细胞,结构,连接性和脉管系统的保存以维持视力。迫切需要找到技术和生物学解决方案,以解决与视网膜细胞功能替代相关的重大挑战。未解决的主要挑战包括产生足够数量的特定细胞类型,实现移植细胞(尤其是感光细胞)的功能整合,以及在不触发免疫反应,炎症和/或重塑的情况下进行视网膜细胞或组织的手术递送。再生医学的进步使三维组织(类器官)的生成成为可能,部分重建了几种组织的解剖结构,生物学复杂性和生理学,这是干细胞替代疗法的重要目标。皿中视网膜组织的衍生为失明的细胞替代疗法创造了新的机会,并满足了保持视网膜结构以恢复视力的需求。在过去的十年中,旨在保持和改善视力的视网膜细胞疗法取得了许多进步。视网膜类器官技术为解决与视网膜细胞功能置换相关的技术和生物学挑战提供了许多解决方案,以实现长期的视力恢复。我们的综述总结了视网膜细胞疗法的进展,重点是人类多能干细胞衍生的视网膜组织,并严格评估了视网膜类器官方法解决主要未满足的临床需求(在视网膜引起的情况下进行视网膜修复和视力恢复)的潜力。变性和眼外伤。我们还分析了视网膜类器官技术在临床上商业化的障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号